Effects of topical timolol for the prevention of radiation-induced dermatitis in breast cancer: a pilot triple-blind, placebo-controlled trial

CONCLUSION: Although the topical formulation of timolol, 0.5% (w/w), was found to reduce the average maximum grade of ARD and increase the mean (SD) time of initial RID occurrence, it showed no effect on ARD, severity, and QOL. However, future clinical trials should be performed to assess timolol gel formulation in larger study populations.TRIAL REGISTRATION: https://irct.ir/ IRCT20190810044500N11 (17/03/2021).PMID:36266613 | DOI:10.1186/s12885-022-10064-x

Source: Cancer Control - October 20, 2022 Category: Cancer & Oncology Authors: Mohsen Nabi-Meybodi Adeleh Sahebnasagh Zahra Hakimi Masoud Shabani Ali Asghar Shakeri Fatemeh Saghafi Source Type: research